· Entitlement Offer to Eligible Shareholders to raise up to approximately A$11 million (before costs), on the basis of 1 New Share for every 1 existing share held by Eligible Shareholders on the Record Date, at an issue price of A$0.006 per Share with 3 free attaching New Options for every 2 New Shares subscribed for.

· Funds raised under the Entitlement Offer will be used to provide funds for conducting a Phase III clinical trial in respect of the Company’s proprietary TPM enhanced CBD soft-gel capsule to manage the symptoms of insomnia, associated manufacturing activities for the clinical trial and costs of the Entitlement Offer.

· View and download the prospectus here: https://ave.investorhub.com/4342997.